BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated May 23, 2023 with regards to Financial Results for the quarter and year ended March 31, 2023, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada Bengaluru Edition) on May 25, 2023. The above information is also available on the website of the Company at www.biocon.com. BIOCON LTD. - 532523 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru. BIOCON LTD. - 532523 - Intimation Under Regulation 30 (6) Of SEBI Listing Obligations And Disclosure Requirements (LODR) Regulations, 2015.
Meeting conducted with Institutional Investors/Research Analysts.
Biocon shares trim most of early gains, end flat amid profit-taking
Shares of Biocon trimmed most of their early gains and ended flat on Wednesday amid profit-taking. During the early trade, the stock climbed nearly 8 per cent after the biotechnology major's consolidated net profit increased 31 per cent for the March quarter. The stock gained 7.12 per cent to Rs 259.50 during the day on the BSE but failed to hold on to the momentum and ended flat. It settled at Rs 243 apiece, marginally up 0.31 pe cent. On the NSE, the stock settled at Rs 242.95 per share, a gain of 0.33 per cent after rallying 7.61 per cent to Rs 260.60 during the day. In volume terms, 18.97 lakh shares of the company were traded on the BSE and over 1.77 crore shares on the NSE during the day. On Tuesday, Biocon said its consolidated net profit increased 31 per cent to Rs 313 crore for the March quarter on the back of robust sales. The company had reported a net profit of Rs 239 crore in January-March 2021-22. Total revenue increased to Rs 3,929 crore in the fourth quarter as a BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find enclosed the presentation on Q4 and full year FY23 Earnings Call conducted today i.e. on May 24, 2023. The same is also available on the website of the Company at www.biocon.com. Further, the Video Recording w.r.t. the Earnings Call is also available on the website of the Company at https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/#1653297216088-5a4e9281-2d49. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed the Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). Biocon Ltd. Results Earnings Call for Q4FY23
Conference Call with Biocon Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Kiran Mazumdar Shaw and Senior Team Q4FY23 Quarterly & FY23 Annual Result Announced for Biocon Ltd.
Biotechnology company Biocon announced Q4FY23 & FY23 results: Q4FY23: Consolidated Revenues for Q4FY23 increased 59% year-on-year (YoY) to Rs 3,929 crore. The revenue for the quarter includes Rs 109 crore of stake dilution gain in Bicara, pursuant to its fundraising during Q4FY23 Core EBITDA (excluding R&D; expense, licensing income, forex, dilution gain in Bicara, and mark-to-market movement on financial instruments) grew 56% to Rs 1,260 crore, representing healthy core operating margins of 35% versus 33% in the same quarter last year. Net R&D; investments for the quarter grew by 79% to Rs 342 crore, representing 12% of revenues exSyngene. EBITDA for the quarter increases 75% to Rs 1,152 crore, representing an EBITDA margin of 29% versus 27% in the same period last year. Profit Before Tax and Exceptional Items increased 30% YoY to Rs 500 crore Net Profit for the quarter, before exceptional items, increased 28% YoY to Rs 335 crore FY23: Consolidated Revenues for FY23 increased 38% year-on-year (YoY) to Rs 11,550 crore. The revenue for the year includes Rs 217 crore of stake dilution gain in Bicara, pursuant to its fundraising during the year. Core EBITDA (excluding R&D; expense, licensing income, forex, dilution gain in Bicara, and mark-to-market movement on financial instruments) grew 43% to Rs 3,807 crore, representing healthy core operating margins of 34% versus 32% last year. Net R&D; investments for the year grew by 88% to Rs 1,119 crore, representing 14% of revenues exSyngene. This demonstrates Biocon’s advancing pipeline that will drive its future growth. EBITDA for the year was up 32% YoY at Rs 2,888 crore, with the EBITDA margin at 25%. Profit Before Tax and Exceptional Items stood at Rs 1,189 crore, up 9% YoY. Net Profit for the year, before exceptional items, stood at Rs 787 crore versus Rs 722 crore in FY22. “FY23 has been a transformational year led by the acquisition of our partnered biosimilars business from Viatris, which has significantly contributed to Biocon’s robust consolidated financials. Revenues grew 38% to Rs 11,550 crore, and EBITDA was at Rs 2,888 crore, reporting a 32% growth. Revenue growth was led by Biosimilars at 61%, Research Services at 23%, and Generics at 13%. R&D; Investments have nearly doubled to Rs 1,119 crore, as we seek to drive future growth. We ended FY23 with a strong Q4 performance where Revenues grew by 59% to Rs 3,929 crore and EBITDA by 75% to Rs 1,152 crore. Biosimilars continue to be the largest business segment for Biocon, with revenues of Rs 2,102 crore, a growth of 114%, exiting the year on a USD 1 billion revenue trajectory.” said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics. Result PDF BIOCON LTD. - 532523 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 ('SEBI Listing Regulation').
In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended March 31, 2023, drawn in accordance with applicable accounting standard. The above information will also be available on the website of the Company at www.biocon.com. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%; EBITDA at Rs 1,152 Cr, Up 75%; Net Profit (before exceptional Items) at Rs 335 Cr, Up 28%' pertaining to the audited consolidated financial results of Biocon Limited for the quarter and year ended March 31, 2023.